| April 1, 2026 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| April 1, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| April 1, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| April 1, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| April 1, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| April 1, 2026 |
JNJ |
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide |
Trial Milestone |
Phase 3 |
| April 1, 2026 |
BNTX |
Results filed (20-F/A) |
Earnings |
— |
| April 1, 2026 |
AAPG |
6-K filed: Foreign issuer report |
Filing |
— |
| April 1, 2026 |
AXSM |
8-K filed: Other event |
Filing |
— |
| April 1, 2026 |
MRNA |
A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of mRNA-3705 in Participants With Isolated Methylmalonic Acidemia |
Trial Milestone |
Phase 1/Phase 2 |
| April 1, 2026 |
PRAX |
A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy |
Trial Milestone |
Phase 1/Phase 2 |
| April 1, 2026 |
INSM |
An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) |
Trial Milestone |
Phase 2/Phase 3 |
| April 1, 2026 |
IMUX |
8-K filed: Other event |
Filing |
— |
| April 1, 2026 |
PTGX |
Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera |
Trial Milestone |
Phase 3 |
| April 1, 2026 |
TLSA |
6-K filed: Foreign issuer report |
Filing |
— |
| April 1, 2026 |
ANRO |
8-K filed: Other event |
Filing |
— |
| April 1, 2026 |
ONCY |
8-K filed: Material agreement, Leadership change, Other event |
Corporate |
— |
| April 1, 2026 |
CATX |
8-K filed: Other event |
Filing |
— |
| April 1, 2026 |
ALDX |
8-K filed: Other event |
Filing |
— |
| April 1, 2026 |
CRDL |
6-K filed: Foreign issuer report |
Filing |
— |
| April 1, 2026 |
HURA |
Quarterly results filed (8-K) |
Earnings |
— |
| April 1, 2026 |
AKBA |
8-K filed: Leadership change |
Corporate |
— |
| April 1, 2026 |
APLM |
6-K filed: Foreign issuer report |
Filing |
— |
| April 2, 2026 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| April 2, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| April 2, 2026 |
BNTX |
6-K filed: Foreign issuer report |
Filing |
— |
| April 2, 2026 |
VNDA |
8-K filed: Leadership change |
Corporate |
— |
| April 2, 2026 |
RARE |
8-K filed: Other event |
Filing |
— |
| April 2, 2026 |
CLDX |
8-K filed: Material agreement, Other event |
Corporate |
— |
| April 2, 2026 |
PHAR |
6-K filed: Foreign issuer report |
Filing |
— |
| April 2, 2026 |
PHAR |
Results filed (20-F) |
Earnings |
— |
| April 2, 2026 |
IMVT |
Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease |
Trial Milestone |
Phase 3 |
| April 2, 2026 |
VTGN |
8-K filed: Listing / standard notice |
Corporate |
— |
| April 2, 2026 |
MDWD |
6-K filed: Foreign issuer report |
Filing |
— |
| April 2, 2026 |
OCS |
A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 2) |
Trial Milestone |
Phase 3 |
| April 2, 2026 |
PHVS |
Results filed (20-F) |
Earnings |
— |
| April 2, 2026 |
PHVS |
6-K filed: Foreign issuer report |
Filing |
— |
| April 2, 2026 |
OTLC |
8-K filed: Material agreement, Other event |
Corporate |
— |
| April 2, 2026 |
TYRA |
8-K filed: Leadership change |
Corporate |
— |
| April 2, 2026 |
MAIA |
8-K filed: Leadership change |
Corporate |
— |
| April 2, 2026 |
ANGO |
Quarterly results filed (8-K) |
Earnings |
— |
| April 2, 2026 |
NERV |
8-K filed: Leadership change, Reg FD disclosure, Other event |
Corporate |
— |
| April 2, 2026 |
COYA |
8-K filed: Leadership change |
Corporate |
— |
| April 2, 2026 |
LPCN |
8-K filed: Other event |
Filing |
— |
| April 2, 2026 |
LPCN |
8-K filed: Other event |
Filing |
— |
| April 2, 2026 |
TCRX |
8-K filed: Leadership change |
Corporate |
— |
| April 2, 2026 |
CNSY |
8-K filed: Other event |
Filing |
— |
| April 2, 2026 |
KPRX |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| April 2, 2026 |
ILMN |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| April 3, 2026 |
ABBV |
Quarterly results filed (8-K) |
Earnings |
— |
| April 3, 2026 |
RYTM |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| April 3, 2026 |
CLYM |
8-K filed: Leadership change |
Corporate |
— |
| April 3, 2026 |
NTHI |
Quarterly results filed (8-K) |
Earnings |
— |
| April 3, 2026 |
BTMD |
8-K filed: Reg FD disclosure |
Filing |
— |
| April 3, 2026 |
ENSC |
8-K filed: Leadership change |
Corporate |
— |
| April 6, 2026 |
LLY |
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight |
Trial Milestone |
Phase 3 |
| April 6, 2026 |
BIIB |
Quarterly results filed (8-K) |
Earnings |
— |
| April 6, 2026 |
NBIX |
8-K filed: Material agreement |
Corporate |
— |
| April 6, 2026 |
JAZZ |
A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in Participants Aged 1 to 65 Years of Age With Tuberous Sclerosis Complex |
Trial Milestone |
Phase 4 |
| April 6, 2026 |
IBRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| April 6, 2026 |
PRAX |
8-K filed: Other event |
Filing |
— |
| April 6, 2026 |
RCUS |
Metabolism, Excretion, and Mass Balance Study of Quemliclustat in Healthy Adult Participants (ARC-24) |
Trial Milestone |
Phase 1 |
| April 6, 2026 |
ONCY |
8-K filed: Other event |
Filing |
— |
| April 6, 2026 |
ONCY |
8-K filed: Other event |
Filing |
— |
| April 6, 2026 |
NERV |
8-K filed: Other event |
Filing |
— |
| April 7, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| April 7, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| April 7, 2026 |
INSM |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| April 7, 2026 |
ASND |
6-K filed: Foreign issuer report |
Filing |
— |
| April 7, 2026 |
SUPN |
8-K filed: Material agreement, Acquisition completed |
Corporate |
— |
| April 7, 2026 |
PVLA |
8-K filed: Other event |
Filing |
— |
| April 7, 2026 |
IKT |
8-K filed: Reg FD disclosure |
Filing |
— |
| April 7, 2026 |
IRD |
8-K filed: Leadership change |
Corporate |
— |
| April 7, 2026 |
IRD |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| April 7, 2026 |
CRBP |
8-K filed: Leadership change, Reg FD disclosure, Other event |
Corporate |
— |
| April 7, 2026 |
EWTX |
A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment |
Trial Milestone |
Phase 1 |
| April 7, 2026 |
STOK |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| April 7, 2026 |
CLYM |
A Phase 1 Study of Budoprutug (TNT119) Subcutaneous and Intravenous Injections in Normal Healthy Volunteers |
Trial Milestone |
EARLY_Phase 1 |
| April 7, 2026 |
ABEO |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| April 7, 2026 |
RADX |
6-K filed: Foreign issuer report |
Filing |
— |
| April 7, 2026 |
OKYO |
6-K filed: Foreign issuer report |
Filing |
— |
| April 7, 2026 |
OTLK |
8-K filed: Other event |
Filing |
— |
| April 7, 2026 |
ACIU |
6-K filed: Foreign issuer report |
Filing |
— |
| April 7, 2026 |
KPRX |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| April 8, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| April 8, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| April 8, 2026 |
REGN |
Quarterly results filed (8-K) |
Earnings |
— |
| April 8, 2026 |
ASND |
6-K filed: Foreign issuer report |
Filing |
— |
| April 8, 2026 |
ASND |
6-K filed: Foreign issuer report |
Filing |
— |
| April 8, 2026 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| April 8, 2026 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| April 8, 2026 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| April 8, 2026 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| April 8, 2026 |
NRIX |
Quarterly results filed (8-K) |
Earnings |
— |
| April 8, 2026 |
PRQR |
6-K filed: Foreign issuer report |
Filing |
— |
| April 8, 2026 |
PRQR |
6-K filed: Foreign issuer report |
Filing |
— |
| April 8, 2026 |
MAIA |
8-K filed: Other event |
Filing |
— |
| April 8, 2026 |
RADX |
6-K filed: Foreign issuer report |
Filing |
— |
| April 8, 2026 |
ENSC |
8-K filed: Material agreement, Other event |
Corporate |
— |
| April 8, 2026 |
HURA |
8-K filed: Leadership change, Other event |
Corporate |
— |
| April 8, 2026 |
CNSY |
8-K filed: Other event |
Filing |
— |
| April 9, 2026 |
AZN |
Results filed (6-K) |
Earnings |
— |
| April 9, 2026 |
MRK |
A Clinical Trial to Evaluate the Effect of Ulonivirine (MK-8507) on Heart Rhythm in Healthy Adults (MK-8507-012) |
Trial Milestone |
Phase 1 |
| April 9, 2026 |
PFE |
A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma. |
Trial Milestone |
Phase 1/Phase 2 |
| April 9, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| April 9, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| April 9, 2026 |
ONC |
A Study of BGB-R046 as Monotherapy and in Combination With Tislelizumab in Solid Tumors |
Trial Milestone |
Phase 1 |
| April 9, 2026 |
IBRX |
Quarterly results filed (8-K) |
Earnings |
— |
| April 9, 2026 |
IDYA |
8-K filed: Other event |
Filing |
— |
| April 9, 2026 |
IVVD |
8-K filed: Other event |
Filing |
— |
| April 9, 2026 |
NVCR |
8-K filed: Leadership change |
Corporate |
— |
| April 9, 2026 |
KYNB |
8-K filed: Listing / standard notice |
Corporate |
— |
| April 9, 2026 |
GOSS |
8-K filed: Listing / standard notice |
Corporate |
— |
| April 9, 2026 |
TMCI |
Quarterly results filed (8-K) |
Earnings |
— |
| April 9, 2026 |
CNSY |
8-K filed: Leadership change |
Corporate |
— |
| April 10, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| April 10, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| April 10, 2026 |
VIR |
8-K filed: Leadership change |
Corporate |
— |
| April 10, 2026 |
ANVS |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| April 10, 2026 |
IMUX |
8-K filed: Leadership change |
Corporate |
— |
| April 10, 2026 |
OCS |
A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1) |
Trial Milestone |
Phase 2/Phase 3 |
| April 10, 2026 |
SLDB |
8-K filed: Leadership change |
Corporate |
— |
| April 10, 2026 |
NTHI |
8-K filed: Material agreement |
Corporate |
— |
| April 10, 2026 |
CRDL |
6-K filed: Foreign issuer report |
Filing |
— |
| April 10, 2026 |
LTRN |
8-K filed: Reg FD disclosure |
Filing |
— |
| April 11, 2026 |
MRK |
A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018) |
Trial Milestone |
Phase 1 |
| April 11, 2026 |
SVA |
Phase IV Clinical Study of sIPV Administration in Adolescent and Adult Populations |
Trial Milestone |
Phase 4 |
| April 13, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| April 13, 2026 |
GSK |
6-K filed: Clinical or regulatory announcement |
Filing |
— |
| April 13, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| April 13, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| April 13, 2026 |
ONC |
An Investigational Study of BG-89894 Tablets in Participants With Advanced Solid Tumors |
Trial Milestone |
Phase 1 |
| April 13, 2026 |
BNTX |
6-K filed: Foreign issuer report |
Filing |
— |
| April 13, 2026 |
RVMD |
8-K filed: Other event |
Filing |
— |
| April 13, 2026 |
XENE |
8-K filed: Leadership change |
Corporate |
— |
| April 13, 2026 |
EYPT |
8-K filed: Other event |
Filing |
— |
| April 13, 2026 |
IDYA |
8-K filed: Other event |
Filing |
— |
| April 13, 2026 |
PHAR |
Results filed (20-F/A) |
Earnings |
— |
| April 13, 2026 |
REPL |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| April 13, 2026 |
PVLA |
8-K filed: Leadership change |
Corporate |
— |
| April 13, 2026 |
VTGN |
8-K filed: Leadership change |
Corporate |
— |
| April 13, 2026 |
CGON |
8-K filed: Leadership change |
Corporate |
— |
| April 13, 2026 |
ALXO |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| April 13, 2026 |
SYRE |
Quarterly results filed (8-K) |
Earnings |
— |
| April 13, 2026 |
SYRE |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| April 13, 2026 |
CLLS |
6-K filed: Foreign issuer report |
Filing |
— |
| April 13, 2026 |
ALLO |
8-K filed: Other event |
Filing |
— |
| April 13, 2026 |
ALLO |
8-K filed: Other event |
Filing |
— |
| April 14, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| April 14, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| April 14, 2026 |
JNJ |
Quarterly results filed (8-K) |
Earnings |
— |
| April 14, 2026 |
ONC |
Quarterly results filed (8-K) |
Earnings |
— |
| April 14, 2026 |
PRAX |
8-K filed: Other event |
Filing |
— |
| April 14, 2026 |
GRFS |
6-K filed: Foreign issuer report |
Filing |
— |
| April 14, 2026 |
TVTX |
8-K filed: Other event |
Filing |
— |
| April 14, 2026 |
IMUX |
8-K filed: Other event |
Filing |
— |
| April 14, 2026 |
CRBP |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| April 14, 2026 |
TLSA |
6-K filed: Foreign issuer report |
Filing |
— |
| April 14, 2026 |
CRDL |
6-K filed: Foreign issuer report |
Filing |
— |
| April 15, 2026 |
LLY |
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan |
Trial Milestone |
Phase 4 |
| April 15, 2026 |
PFE |
A Study to Learn About How the Body Processes the Study Medicine Called PF-07328948 in Healthy Chinese Adults |
Trial Milestone |
Phase 1 |
| April 15, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| April 15, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| April 15, 2026 |
ABBV |
A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS) |
Trial Milestone |
Phase 1 |
| April 15, 2026 |
SNY |
6-K filed: Foreign issuer report |
Filing |
— |
| April 15, 2026 |
AAPG |
APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors |
Trial Milestone |
Phase 1/Phase 2 |
| April 15, 2026 |
AAPG |
A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus. |
Trial Milestone |
Phase 1/Phase 2 |
| April 15, 2026 |
VTGN |
A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder |
Trial Milestone |
Phase 2 |
| April 15, 2026 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| April 15, 2026 |
TNGX |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| April 15, 2026 |
TRAW |
Quarterly results filed (8-K) |
Earnings |
— |
| April 15, 2026 |
TRAW |
8-K filed: Material agreement, Other event |
Corporate |
— |
| April 15, 2026 |
WVE |
8-K filed: Material agreement, Other event |
Corporate |
— |
| April 15, 2026 |
RVPH |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| April 15, 2026 |
ALLO |
8-K filed: Other event |
Filing |
— |
| April 16, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| April 16, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| April 16, 2026 |
SNY |
Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older |
Trial Milestone |
Phase 1/Phase 2 |
| April 16, 2026 |
TAK |
A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP) |
Trial Milestone |
Phase 2 |
| April 16, 2026 |
RVMD |
8-K filed: Other event |
Filing |
— |
| April 16, 2026 |
ASND |
6-K filed: Foreign issuer report |
Filing |
— |
| April 16, 2026 |
PHAR |
6-K filed: Foreign issuer report |
Filing |
— |
| April 16, 2026 |
MGTX |
8-K filed: Material agreement |
Corporate |
— |
| April 16, 2026 |
MGTX |
8-K filed: Material agreement, Acquisition completed, Reg FD disclosure, Other event |
Corporate |
— |
| April 16, 2026 |
MGTX |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| April 16, 2026 |
CRBP |
8-K filed: Leadership change |
Corporate |
— |
| April 16, 2026 |
OTLC |
8-K filed: Other event |
Filing |
— |
| April 16, 2026 |
TLSA |
6-K filed: Foreign issuer report |
Filing |
— |
| April 16, 2026 |
MAIA |
8-K filed: Other event |
Filing |
— |
| April 16, 2026 |
SYRE |
8-K filed: Material agreement |
Corporate |
— |
| April 16, 2026 |
NTHI |
8-K filed: Reg FD disclosure |
Filing |
— |
| April 16, 2026 |
RADX |
6-K filed: Foreign issuer report |
Filing |
— |
| April 16, 2026 |
ACHV |
8-K filed: Material agreement, Leadership change, Reg FD disclosure |
Corporate |
— |
| April 16, 2026 |
FTH |
8-K filed: Leadership change |
Corporate |
— |
| April 17, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| April 17, 2026 |
ABBV |
Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease |
Trial Milestone |
Phase 3 |
| April 17, 2026 |
AMGN |
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis |
Trial Milestone |
Phase 3 |
| April 17, 2026 |
GILD |
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1 |
Trial Milestone |
Phase 3 |
| April 17, 2026 |
RVMD |
8-K filed: Material agreement, Other event |
Corporate |
— |
| April 17, 2026 |
GRFS |
Results filed (20-F) |
Earnings |
— |
| April 17, 2026 |
TRVI |
Quarterly results filed (8-K) |
Earnings |
— |
| April 17, 2026 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| April 17, 2026 |
IMTX |
6-K filed: Foreign issuer report |
Filing |
— |
| April 17, 2026 |
TYRA |
8-K filed: Leadership change |
Corporate |
— |
| April 17, 2026 |
BCRX |
A Study of Avoralstat In Participants With Diabetic Macular Edema |
Trial Milestone |
Phase 1 |
| April 18, 2026 |
MBX |
Study to Evaluate Efficacy and Dose Response of Imapextide (STEADI) |
Trial Milestone |
Phase 2 |
| April 20, 2026 |
AZN |
6-K filed: Clinical or regulatory announcement |
Filing |
— |
| April 20, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| April 20, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| April 20, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| April 20, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| April 20, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| April 20, 2026 |
ARGX |
6-K filed: Foreign issuer report |
Filing |
— |
| April 20, 2026 |
AAPG |
6-K filed: Foreign issuer report |
Filing |
— |
| April 20, 2026 |
BMRN |
Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior Inhibitors |
Trial Milestone |
Phase 1/Phase 2 |
| April 20, 2026 |
INBS |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| April 20, 2026 |
KLRA |
8-K filed: Other event |
Filing |
— |
| April 20, 2026 |
ASND |
6-K filed: Foreign issuer report |
Filing |
— |
| April 20, 2026 |
CABA |
8-K filed: Other event |
Filing |
— |
| April 20, 2026 |
RCUS |
8-K filed: Other event |
Filing |
— |
| April 20, 2026 |
BCYC |
8-K filed: Other event |
Filing |
— |
| April 20, 2026 |
NKTR |
8-K filed: Reg FD disclosure |
Filing |
— |
| April 20, 2026 |
NKTR |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| April 20, 2026 |
ABVX |
6-K filed: Foreign issuer report |
Filing |
— |
| April 20, 2026 |
KYTX |
8-K filed: Reg FD disclosure |
Filing |
— |
| April 20, 2026 |
NGNE |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| April 20, 2026 |
CATX |
8-K filed: Other event |
Filing |
— |
| April 20, 2026 |
RADX |
6-K filed: Foreign issuer report |
Filing |
— |
| April 20, 2026 |
ALDX |
8-K filed: Leadership change |
Corporate |
— |
| April 21, 2026 |
AZN |
A Study to Investigate Efficacy and Safety of Tozorakimab Injections Compared With Placebo in Adult Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations and Elevated Eosinophils |
Trial Milestone |
Phase 2 |
| April 21, 2026 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| April 21, 2026 |
PFE |
A Study of MET233 in Individuals With Obesity or Overweight |
Trial Milestone |
Phase 1 |
| April 21, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| April 21, 2026 |
SNY |
Study of an RSV-hMPV-PIV3 Trivalent Vaccine Candidate VXB-251 in Older Adults |
Trial Milestone |
Phase 1 |
| April 21, 2026 |
NVO |
A Research Study of a New Medicine NNC0363-1063 in Participants With Type 1 Diabetes |
Trial Milestone |
Phase 1 |
| April 21, 2026 |
NVO |
A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors |
Trial Milestone |
Phase 3 |
| April 21, 2026 |
ONC |
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer |
Trial Milestone |
Phase 1 |
| April 21, 2026 |
IONS |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| April 21, 2026 |
ASND |
6-K filed: Foreign issuer report |
Filing |
— |
| April 21, 2026 |
ASND |
6-K filed: Foreign issuer report |
Filing |
— |
| April 21, 2026 |
RAPP |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| April 21, 2026 |
VTGN |
Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4) |
Trial Milestone |
Phase 3 |
| April 21, 2026 |
BLTE |
6-K filed: Foreign issuer report |
Filing |
— |
| April 21, 2026 |
OCS |
6-K filed: Foreign issuer report |
Filing |
— |
| April 21, 2026 |
IMTX |
6-K filed: Foreign issuer report |
Filing |
— |
| April 21, 2026 |
PVCT |
8-K filed: Other event |
Filing |
— |
| April 21, 2026 |
SGMT |
8-K filed: Leadership change, Other event |
Corporate |
— |
| April 21, 2026 |
WVE |
8-K filed: Other event |
Filing |
— |
| April 21, 2026 |
ERAS |
8-K filed: Other event |
Filing |
— |
| April 21, 2026 |
LPCN |
8-K filed: Leadership change |
Corporate |
— |
| April 21, 2026 |
OTLK |
8-K filed: Other event |
Filing |
— |
| April 21, 2026 |
CNSY |
8-K filed: Other event |
Filing |
— |
| April 21, 2026 |
CERS |
8-K filed: Leadership change |
Corporate |
— |
| April 21, 2026 |
GNPX |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| April 22, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| April 22, 2026 |
AMGN |
8-K filed: Leadership change |
Corporate |
— |
| April 22, 2026 |
NVO |
A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight |
Trial Milestone |
Phase 3 |
| April 22, 2026 |
VNDA |
8-K filed: Leadership change |
Corporate |
— |
| April 22, 2026 |
AAPG |
6-K filed: Foreign issuer report |
Filing |
— |
| April 22, 2026 |
DFTX |
8-K filed: Other event |
Filing |
— |
| April 22, 2026 |
BSX |
Quarterly results filed (8-K) |
Earnings |
— |
| April 22, 2026 |
SUPN |
Quarterly results filed (8-K) |
Earnings |
— |
| April 22, 2026 |
TENX |
8-K filed: Leadership change, Other event |
Corporate |
— |
| April 22, 2026 |
KYTX |
8-K filed: Reg FD disclosure |
Filing |
— |
| April 22, 2026 |
KYTX |
8-K filed: Reg FD disclosure |
Filing |
— |
| April 22, 2026 |
AMRX |
Quarterly results filed (8-K) |
Earnings |
— |
| April 22, 2026 |
HURA |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| April 22, 2026 |
SPRB |
8-K filed: Material agreement, Other event |
Corporate |
— |
| April 22, 2026 |
MAZE |
8-K filed: Other event |
Filing |
— |
| April 23, 2026 |
AZN |
6-K filed: Corporate announcement |
Corporate |
— |
| April 23, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| April 23, 2026 |
SNY |
6-K filed: Foreign issuer report |
Filing |
— |
| April 23, 2026 |
GILD |
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 |
Trial Milestone |
Phase 3 |
| April 23, 2026 |
ONC |
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification |
Trial Milestone |
Phase 1 |
| April 23, 2026 |
ONC |
BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors |
Trial Milestone |
Phase 1 |
| April 23, 2026 |
BMRN |
8-K filed: Other event |
Filing |
— |
| April 23, 2026 |
CANF |
6-K filed: Foreign issuer report |
Filing |
— |
| April 23, 2026 |
IMUX |
8-K filed: Other event |
Filing |
— |
| April 23, 2026 |
NKTR |
8-K filed: Material agreement, Other event |
Corporate |
— |
| April 23, 2026 |
GRCE |
8-K filed: Other event |
Filing |
— |
| April 23, 2026 |
CRVS |
8-K filed: Leadership change |
Corporate |
— |
| April 23, 2026 |
ANGO |
8-K filed: Other event |
Filing |
— |
| April 23, 2026 |
MCUJF |
6-K filed: Foreign issuer report |
Filing |
— |
| April 23, 2026 |
RADX |
Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases |
Trial Milestone |
Phase 2 |
| April 23, 2026 |
RADX |
6-K filed: Foreign issuer report |
Filing |
— |
| April 23, 2026 |
OTLK |
8-K filed: Other event |
Filing |
— |
| April 23, 2026 |
MBRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| April 23, 2026 |
WST |
Quarterly results filed (8-K) |
Earnings |
— |
| April 24, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| April 24, 2026 |
CLDX |
A Phase I Study of CDX-622 |
Trial Milestone |
Phase 1 |
| April 24, 2026 |
HUMA |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| April 24, 2026 |
MGTX |
8-K filed: Material agreement |
Corporate |
— |
| April 24, 2026 |
NVCR |
8-K/A filed: Leadership change |
Corporate |
— |
| April 24, 2026 |
ALT |
8-K filed: Material agreement |
Corporate |
— |
| April 24, 2026 |
MCUJF |
6-K filed: Foreign issuer report |
Filing |
— |
| April 24, 2026 |
MCUJF |
Results filed (20-F) |
Earnings |
— |
| April 24, 2026 |
NTHI |
8-K filed: Material agreement |
Corporate |
— |
| April 24, 2026 |
QTTB |
8-K filed: Other event |
Filing |
— |
| April 24, 2026 |
APLM |
Results filed (20-F) |
Earnings |
— |
| April 27, 2026 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| April 27, 2026 |
GSK |
6-K filed: Clinical or regulatory announcement |
Filing |
— |
| April 27, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| April 27, 2026 |
SNY |
6-K filed: Foreign issuer report |
Filing |
— |
| April 27, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| April 27, 2026 |
ONC |
A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation |
Trial Milestone |
Phase 3 |
| April 27, 2026 |
BMRN |
8-K filed: Material agreement, Acquisition completed, Reg FD disclosure |
Corporate |
— |
| April 27, 2026 |
MIRM |
8-K filed: Other event |
Filing |
— |
| April 27, 2026 |
NTLA |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| April 27, 2026 |
MANE |
Quarterly results filed (8-K) |
Earnings |
— |
| April 27, 2026 |
MANE |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| April 27, 2026 |
GRCE |
8-K filed: Other event |
Filing |
— |
| April 27, 2026 |
ORKA |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| April 27, 2026 |
RLAY |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| April 27, 2026 |
ONCY |
8-K filed: Other event |
Filing |
— |
| April 27, 2026 |
SGMT |
8-K filed: Reg FD disclosure |
Filing |
— |
| April 27, 2026 |
SGMT |
Quarterly results filed (8-K) |
Earnings |
— |
| April 27, 2026 |
NGEN |
6-K filed: Foreign issuer report |
Filing |
— |
| April 27, 2026 |
OGN |
8-K filed: Material agreement, Leadership change, Reg FD disclosure |
Corporate |
— |
| April 27, 2026 |
CRMD |
8-K filed: Reg FD disclosure |
Filing |
— |
| April 27, 2026 |
ERAS |
8-K filed: Other event |
Filing |
— |
| April 27, 2026 |
ERAS |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| April 27, 2026 |
CLLS |
6-K filed: Foreign issuer report |
Filing |
— |
| April 27, 2026 |
XNCR |
8-K filed: Leadership change |
Corporate |
— |
| April 27, 2026 |
APLM |
6-K filed: Foreign issuer report |
Filing |
— |
| April 28, 2026 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| April 28, 2026 |
NVS |
6-K filed: Foreign issuer report |
Filing |
— |
| April 28, 2026 |
LLY |
A Study of LY4005130 in Healthy Participants |
Trial Milestone |
Phase 1 |
| April 28, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| April 28, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| April 28, 2026 |
AMGN |
A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome |
Trial Milestone |
Phase 2 |
| April 28, 2026 |
GILD |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| April 28, 2026 |
INCY |
Quarterly results filed (8-K) |
Earnings |
— |
| April 28, 2026 |
MDGL |
8-K filed: Leadership change |
Corporate |
— |
| April 28, 2026 |
VTGN |
8-K filed: Other event |
Filing |
— |
| April 28, 2026 |
IMUX |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| April 28, 2026 |
ABVX |
ABTECT - Maintenance |
Trial Milestone |
Phase 3 |
| April 28, 2026 |
KNSA |
Quarterly results filed (8-K) |
Earnings |
— |
| April 28, 2026 |
CLYM |
8-K filed: Material agreement, Other event |
Corporate |
— |
| April 28, 2026 |
SGMT |
8-K filed: Material agreement |
Corporate |
— |
| April 28, 2026 |
BLRX |
6-K filed: Foreign issuer report |
Filing |
— |
| April 28, 2026 |
WVE |
Quarterly results filed (8-K) |
Earnings |
— |
| April 28, 2026 |
CRDL |
6-K filed: Foreign issuer report |
Filing |
— |
| April 28, 2026 |
GNPX |
8-K filed: Other event |
Filing |
— |
| April 29, 2026 |
AZN |
Results filed (6-K) |
Earnings |
— |
| April 29, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| April 29, 2026 |
GSK |
Results filed (6-K) |
Earnings |
— |
| April 29, 2026 |
ABBV |
Quarterly results filed (8-K) |
Earnings |
— |
| April 29, 2026 |
SNY |
6-K filed: Foreign issuer report |
Filing |
— |
| April 29, 2026 |
REGN |
A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies |
Trial Milestone |
Phase 1 |
| April 29, 2026 |
REGN |
Quarterly results filed (8-K) |
Earnings |
— |
| April 29, 2026 |
BIIB |
Quarterly results filed (8-K) |
Earnings |
— |
| April 29, 2026 |
IONS |
Quarterly results filed (8-K) |
Earnings |
— |
| April 29, 2026 |
AGIO |
Quarterly results filed (8-K) |
Earnings |
— |
| April 29, 2026 |
AAPG |
Results filed (20-F) |
Earnings |
— |
| April 29, 2026 |
OCUL |
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration |
Trial Milestone |
Phase 3 |
| April 29, 2026 |
TEVA |
Quarterly results filed (8-K) |
Earnings |
— |
| April 29, 2026 |
RCUS |
A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies |
Trial Milestone |
Phase 1 |
| April 29, 2026 |
GKOS |
Quarterly results filed (8-K) |
Earnings |
— |
| April 29, 2026 |
OLMA |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| April 29, 2026 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| April 29, 2026 |
EWTX |
A Study of EDG-15400 in Healthy Adults |
Trial Milestone |
Phase 1 |
| April 29, 2026 |
PTCHF |
Results filed (20-F) |
Earnings |
— |
| April 29, 2026 |
PTCHF |
6-K filed: Foreign issuer report |
Filing |
— |
| April 29, 2026 |
PTCHF |
6-K filed: Foreign issuer report |
Filing |
— |
| April 29, 2026 |
MPLT |
8-K filed: Leadership change |
Corporate |
— |
| April 29, 2026 |
OKYO |
6-K filed: Foreign issuer report |
Filing |
— |
| April 29, 2026 |
LKFT |
6-K filed: Foreign issuer report |
Filing |
— |
| April 29, 2026 |
VRTX |
8-K filed: Leadership change |
Corporate |
— |
| April 29, 2026 |
CERS |
INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections |
Trial Milestone |
Phase 3 |
| April 30, 2026 |
MRK |
Quarterly results filed (8-K) |
Earnings |
— |
| April 30, 2026 |
LLY |
Quarterly results filed (8-K) |
Earnings |
— |
| April 30, 2026 |
BMY |
Quarterly results filed (8-K) |
Earnings |
— |
| April 30, 2026 |
AMGN |
Quarterly results filed (8-K) |
Earnings |
— |
| April 30, 2026 |
SVA |
Results filed (20-F) |
Earnings |
— |
| April 30, 2026 |
AXSM |
8-K filed: Other event |
Filing |
— |
| April 30, 2026 |
ALNY |
Quarterly results filed (8-K) |
Earnings |
— |
| April 30, 2026 |
SMMT |
Quarterly results filed (8-K) |
Earnings |
— |
| April 30, 2026 |
NTLA |
Quarterly results filed (8-K) |
Earnings |
— |
| April 30, 2026 |
CANF |
6-K filed: Foreign issuer report |
Filing |
— |
| April 30, 2026 |
CORT |
Quarterly results filed (8-K) |
Earnings |
— |
| April 30, 2026 |
BCYC |
Quarterly results filed (8-K) |
Earnings |
— |
| April 30, 2026 |
RNAC |
Quarterly results filed (8-K) |
Earnings |
— |
| April 30, 2026 |
AWHL |
8-K filed: Leadership change |
Corporate |
— |
| April 30, 2026 |
SNDX |
Quarterly results filed (8-K) |
Earnings |
— |
| April 30, 2026 |
AVIR |
Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function |
Trial Milestone |
Phase 1 |
| April 30, 2026 |
NVCR |
Quarterly results filed (8-K) |
Earnings |
— |
| April 30, 2026 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| April 30, 2026 |
UTHR |
A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension |
Trial Milestone |
Phase 4 |
| April 30, 2026 |
ORKA |
Quarterly results filed (8-K) |
Earnings |
— |
| April 30, 2026 |
QURE |
8-K filed: Reg FD disclosure |
Filing |
— |
| April 30, 2026 |
PHAT |
Quarterly results filed (8-K) |
Earnings |
— |
| April 30, 2026 |
PRQR |
6-K filed: Foreign issuer report |
Filing |
— |
| April 30, 2026 |
TLSA |
Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis |
Trial Milestone |
Phase 2 |
| April 30, 2026 |
CRVS |
A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma |
Trial Milestone |
Phase 1 |
| April 30, 2026 |
PCRX |
Quarterly results filed (8-K) |
Earnings |
— |
| April 30, 2026 |
LXEO |
8-K filed: Leadership change |
Corporate |
— |
| April 30, 2026 |
RXRX |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| April 30, 2026 |
VALN |
6-K filed: Foreign issuer report |
Filing |
— |
| April 30, 2026 |
HALO |
8-K filed: Leadership change |
Corporate |
— |
| April 30, 2026 |
ARDX |
Quarterly results filed (8-K) |
Earnings |
— |
| April 30, 2026 |
KYMR |
Quarterly results filed (8-K) |
Earnings |
— |
| April 30, 2026 |
OGN |
Quarterly results filed (8-K) |
Earnings |
— |
| April 30, 2026 |
LXRX |
8-K filed: Material agreement |
Corporate |
— |
| April 30, 2026 |
HURA |
8-K/A filed: Other event |
Filing |
— |
| April 30, 2026 |
ACIU |
6-K filed: Foreign issuer report |
Filing |
— |
| April 30, 2026 |
ACIU |
6-K filed: Foreign issuer report |
Filing |
— |
| April 30, 2026 |
CERS |
Quarterly results filed (8-K) |
Earnings |
— |
| April 30, 2026 |
GNPX |
8-K filed: Other event |
Filing |
— |
| April 30, 2026 |
ILMN |
Quarterly results filed (8-K) |
Earnings |
— |